Immunoscore and Immunoprofiling in cancer

An update from the melanoma and immunotherapy bridge 2015

J. Galon, B. A. Fox, C. B. Bifulco, G. Masucci, T. Rau, G. Botti, F. M. Marincola, G. Ciliberto, F. Pages, P. A. Ascierto, M. Capone

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The fifth "Melanoma Bridge Meeting" took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.

Original languageEnglish
Article number273
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - Sep 20 2016

Fingerprint

Immunotherapy
Tumors
Melanoma
Neoplasms
Tumor Microenvironment
Infiltration
Immune system
Mutation
Neoplasm Antigens
Tumor Biomarkers
Immune System

Keywords

  • Immunoprofiling
  • Immunoscore
  • Melanoma

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immunoscore and Immunoprofiling in cancer : An update from the melanoma and immunotherapy bridge 2015. / Galon, J.; Fox, B. A.; Bifulco, C. B.; Masucci, G.; Rau, T.; Botti, G.; Marincola, F. M.; Ciliberto, G.; Pages, F.; Ascierto, P. A.; Capone, M.

In: Journal of Translational Medicine, Vol. 14, No. 1, 273, 20.09.2016.

Research output: Contribution to journalArticle

@article{f5cf77a5fa15472f995ec6f4aac03163,
title = "Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015",
abstract = "The fifth {"}Melanoma Bridge Meeting{"} took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.",
keywords = "Immunoprofiling, Immunoscore, Melanoma",
author = "J. Galon and Fox, {B. A.} and Bifulco, {C. B.} and G. Masucci and T. Rau and G. Botti and Marincola, {F. M.} and G. Ciliberto and F. Pages and Ascierto, {P. A.} and M. Capone",
year = "2016",
month = "9",
day = "20",
doi = "10.1186/s12967-016-1029-z",
language = "English",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Immunoscore and Immunoprofiling in cancer

T2 - An update from the melanoma and immunotherapy bridge 2015

AU - Galon, J.

AU - Fox, B. A.

AU - Bifulco, C. B.

AU - Masucci, G.

AU - Rau, T.

AU - Botti, G.

AU - Marincola, F. M.

AU - Ciliberto, G.

AU - Pages, F.

AU - Ascierto, P. A.

AU - Capone, M.

PY - 2016/9/20

Y1 - 2016/9/20

N2 - The fifth "Melanoma Bridge Meeting" took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.

AB - The fifth "Melanoma Bridge Meeting" took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.

KW - Immunoprofiling

KW - Immunoscore

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84988600706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988600706&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-1029-z

DO - 10.1186/s12967-016-1029-z

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 273

ER -